Expression characteristics, prognostic value, and immune-related analysis of PPP2R1A in lung adenocarcinoma
Authors:
Open Access
- 2 December 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1652629
Abstract
Introduction: Lung adenocarcinoma (LUAD) is a major subtype of lung cancer with poor prognosis. The protein phosphatase 2 regulatory subunit A alpha (PPP2R1A) plays complex roles in tumorigenesis, but its function and clinical significance in LUAD remain unclear. Methods: We analyzed PPP2R1A expression across cancers using the Xiantao Academic Online tool and TCGA data. Diagnostic potential was evaluated via ROC curve analysis. Prognostic value was assessed using Kaplan-Meier survival and Cox regression analyses. Protein-protein interaction networks and functional enrichment analyses were conducted to explore molecular mechanisms. Immune infiltration patterns were investigated using TIMER2.0. Experimental validation was performed through CRISPR/Cas9-mediated knockdown in A549 cells, followed by functional assays including CCK-8, clonogenic, wound healing, and Transwell assays. Results: PPP2R1A was significantly upregulated in LUAD tissues compared to normal controls (P < 0.05). It demonstrated modest diagnostic value with an AUC of 0.593. High PPP2R1A expression was associated with poor progression-free survival (FP) and overall survival (OS), particularly in early-stage disease. PPP2R1A expression correlated with advanced N stage and tumor stage. Functional enrichment analysis revealed involvement in protein dephosphorylation, cell cycle regulation, and metabolic pathways. Immune infiltration analysis showed significant correlations with macrophage and CD4+ T cell infiltration. Experimental validation confirmed that PPP2R1A knockdown significantly inhibited LUAD cell proliferation, migration, and invasion (P < 0.01). Discussion: PPP2R1A is overexpressed in LUAD and associated with poor prognosis, potentially serving as an oncogene by regulating key signaling pathways and immune microenvironment. Its knockdown suppresses malignant phenotypes, highlighting its potential as both a prognostic biomarker and therapeutic target in LUAD.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumorsCancer Immunology, Immunotherapy, 2025
- Silencing PPP2R1A inhibits the progression of gastric cancer cellsJournal of Cancer Research and Clinical Oncology, 2025
- PP2A B55α inhibits epithelial-mesenchymal transition via regulation of Slug expression in non-small cell lung cancerCancer Letters, 2024
- Predicting potential therapeutic targets and small molecule drugs for early-stage lung adenocarcinomaBiomedicine & Pharmacotherapy, 2024
- Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinomaComputers in Biology and Medicine, 2023
- CPSF6-mediated XBP1 3’UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinomaDrug Resistance Updates, 2023
- PP2A regulates metastasis and vasculogenic mimicry formation via PI3K/AKT/ZEB1 axis in non-small cell lung cancersJournal of Pharmacological Sciences, 2022
- PP2A protects podocytes against Adriamycin-induced injury and epithelial-to-mesenchymal transition via suppressing JIP4/p38-MAPK pathwayCytotechnology, 2021
- Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric CancerCancer Cell, 2020
- Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancerJournal of Molecular Medicine, 2016